Radiation plus two cancer drugs tested in advanced liver cancer trial
NCT ID NCT05488522
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests whether adding precise radiation (SBRT) to a standard two-drug combination (atezolizumab and bevacizumab) is safe and tolerable for people with advanced liver cancer that cannot be treated with surgery. The trial enrolls 18 participants and will also look at how well the tumors respond. The goal is to find a dose and schedule for future larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stereotactic body radiotherapy (SBRT) plus atezolizumab and bevacizumab
What this could lead to
If successful, this could point toward a new combination treatment that helps control advanced liver cancer when standard therapies are no longer effective.
What could go wrong
This is a very early (phase I) trial with only 18 participants, focused on safety and dosing. It is not designed to prove the combination works, and side effects from radiation or the drugs could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Abramson Cancer Center of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104-4283, United States
Contact Phone: •••-•••-••••